All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 5, 2021
Home » Blogs » BioWorld MedTech Perspectives » Physician Payment Sunshine Act implementation right around the corner

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Physician Payment Sunshine Act implementation right around the corner

March 8, 2013
By Omar Ford
No Comments
Are you ready

Are you ready? That's probably the most appropriate way to start off a blog entry concerning the soon to be implemented Physician Payment Sunshine Act. And the question isn't just for med-tech companies alone, it's for the physicians as well.

A recent survey conducted by MMIS, a company that develops secure communication solutions for firms, shows that physicians still aren't completely aware of the provision- which is set to go into effect in August (a little more than 4 months away. Yikes!). In a conversation with Medical Device Daily, Michaeline Daboul president/CEO MMIS said that survey results of the more than 1,000 physicians questioned show that more than half admitted they didn't know that the law required medical device companies and pharmaceutical companies to report on expenditures annually, without physician review of the data to correct any inconsistencies or errors prior to submission to the government.

Now there are probably tons of reasons why these physicians were unprepared for certain aspects of this law. Perhaps firms were hedging their bets that the Presidential election would go another way and that many provisions of the Affordable Care Act would be thrown out. Well that didn't happen and now med-tech companies and physicians have to deal with the law - or face hefty fines and damaged relationships if they aren't in compliance.

But that's where companies like MMIS come in. The company has designed a network that will allow physicians to become more familiar with the process and also view and possibly dispute payment entries prior to these said entries being made public.

It's an interesting network and MMIS has been talking to MDD about this for the last two years.

Obviously this company is ready, the question is are the med-tech firms and physicians out there ready?

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 4.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing